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See Editorial, pages 687–688Background & Aims: Primary sclerosing cholangitis (PSC) is
associated with increased mortality. Cardiovascular disease is a
leading cause of death in the Western world. We examined the
risk of cardiovascular disease and diabetes (type 1 and type 2)
in patients with PSC and their ﬁrst-degree relatives.
Methods: This prospective multicentre cohort study included
678 individuals with PSC diagnosed between 1970 and
2004, and 6347 non-PSC reference individuals matched for
age, and sex. Through linkage of the Swedish Multigeneration
Register we identiﬁed 3139 ﬁrst-degree relatives to PSC
patients and 30,953 ﬁrst-degree relatives to the matched
comparison cohort. We retrieved data on cardiovascular dis-
ease and type 1 and type 2 diabetes (T1D and T2D) from
the National Patient Register, and then examined the associa-
tion with PSC or having a family history of PSC using Poisson
regression.
Results: During 125,127 person-years of follow-up, 203 individu-
als with PSC had a diagnosis of cardiovascular disease. This corre-
sponded to a 3.34-fold increased relative risk (RR) of
cardiovascular disease in individuals with PSC (95% CI = 2.86–
3.91). The highest risk estimates were seen for diseases of the
arteries, veins, and lymphatic vessels while the RR was neutral
for ischemic heart disease (0.90) or only slightly elevated for
cerebrovascular disease (1.74). Meanwhile, PSC ﬁrst-degree rela-
tives were at no increased risk of cardiovascular disease
(RR = 0.87; 95% CI = 0.80–0.95). Individuals with PSC (RR = 7.95;
95% CI = 4.82–13.12), and to some extent also their ﬁrst-degree
relatives (RR = 1.73; 95% CI = 1.19–2.52) were at increased riskJournal of Hepatology 20
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cholangitis; T1D, type 1 diabetes; T2D, type 2 diabetes.of T1D. Also for T2D were the RR is higher in individuals with
PSC (RR = 2.54; 95% CI = 1.56–4.13) than in PSC ﬁrst-degree rela-
tives (RR = 0.81; 95% CI = 0.65–1.02).
Conclusions: PSC was associated with T1D, T2D, and non-ische-
mic cardiovascular disease. In contrast, ﬁrst-degree relatives to
PSC patients were only at a moderately increased risk of T1D,
and at no increased risk of either cardiovascular disease or T2D.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Primary sclerosing cholangitis (PSC) occurs in about 4–15/
100,000 people [1–3]. It is an idiopathic cholestatic disorder with
intra- and extrahepatic ﬁbrosis and inﬂammation [4]. This causes
duct destruction and ultimately biliary cirrhosis and liver failure.
There is no available treatment that inﬂuences disease progres-
sion, and the prognosis of PSC is poor [1,5]. An older Swedish
study with 305 PSC patients found a median survival from time
of PSC diagnosis to either death or liver transplantation of
12 years [5], and in a recent paper by de Valle et al. fromWestern
Sweden, PSC was associated with a 4-fold increased risk in mor-
tality [6]. Similar mortality risks have also been reported from the
British General Practice Research Database [1].
Bile duct cancer is more prevalent in PSC patients and contrib-
utes to the excess of both overall mortality and morbidity in PSC
[1,5,6]. Less is however known about PSC and the risk of cardiovas-
cular disease and type 1 and type 2 diabetes (T1D and T2D). In a
recent paper from the Netherlands, Lamberts et al. reported that
9 out of 241 patients (3.7%) with PSC developed T1D [7]. Although
the authors did not calculate any relative risk for T1D, a prevalence
of 3–4% is likely to constitute a substantial risk increase since the
prevalence of T1D in the general population of the Netherlands is
at the most 1% (proportion of individuals in the Netherlands who
receive insulin treatment for diabetes: T1D and T2D) [8], and there
is a need for more precise estimates of the T1D risk in PSC.
Cardiovascular disease is the leading cause of death in the
Western world [9], and some 500,000 people die from ischemic14 vol. 60 j 802–808
Table 1. Characteristics of ﬁrst-degree relatives.
Relatives of 
PSC1 patients
Relatives of 
subjects without PSC
Total
Mean age at first record
3139 30,953
Offspring 930 9773
Male (%) 496 (53.3) 5035 (51.5)
Siblings 1030 10,529
Male (%) 540 (52.0) 5352 (50.8)
Parents 1170 10,651
Male (%) 576 (49.2) 5211 (48.9)
of CVD2 (SD)
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heart disease each year in the US, with additional deaths from
stroke (stroke being the second most common cause of death
[10]). Despite the impact of cardiovascular disease on public
health, and observations of dyslipidemia in PSC [11–13] we are
not aware of any population-based study on the risk of cardiovas-
cular disease in PSC.
The purpose of this study was to investigate the risk of cardio-
vascular disease and diabetes (type 1 and 2) in patients with PSC
and their ﬁrst-degree relatives. We hypothesized that individuals
with PSC would be at increased risk especially of T1D since this
latter disease shares several of the immune-mediated traits of
PSC. Furthermore we expected to see an increased risk of cardio-
vascular disease in PSC, but less so in their ﬁrst-degree relatives,
since the latter are not exposed to PSC-related inﬂammation.Offspring 24 (13) 25 (13)
Siblings 48 (13) 47 (13)
Parents 68 (13) 68 (13)
Mean follow-up 
time (SD)
29.6 (12) 29.3 (12)
1Primary sclerosing cholangitis.
2Cardiovascular disease.Patients and methods
Through the personal identity number [14] we linked data on clinically veriﬁed
PSC and nationwide data on cardiovascular disease, T1D and T2D from Swedish
registers.
PSC deﬁnition
Hepatologists representing ten Swedish university hospitals have prospectively
reported cases of PSC to the Swedish Internal Medicine Liver Club since 1970.
The ten university hospitals include three transplantation centres. In this study
the PSC diagnosis was based on a combination of biochemical, clinical, and chol-
angiographic data in accordance with Wiesner and LaRusso [15]. In addition, the
PSC diagnosis was conﬁrmed against patient charts. We deﬁned the onset of PSC
as equal to the ﬁrst cholangiographic examination with signs of PSC (the patients
should also have additional proof of PSC) [16].
We initially identiﬁed 700 individuals with PSC. Of these, we excluded 22
(because they had emigrated from Sweden and were no longer available for
matching), leaving 678 PSC patients for the main analyses of this study. Detailed
characteristics of these individuals have been described previously [16], but in
short some 465 (69%) were male, and 545 (80%) had a concomitant diagnosis
of IBD (most often ulcerative colitis (n = 463, i.e., 68% of the PSC cohort)). The
mean age at onset at diagnosis was 36 years (SD: ±12), and 142 individuals had
a liver transplantation during follow-up (21%).
Comparison cohort
Each case with PSC was matched with up to ten individuals from general popu-
lation for age and calendar year (exact years), sex, and county (n = 6347).
First-degree relatives
In order to explore if potential associations between PSC, cardiovascular disease
and diabetes (T1D or T2D), were mediated by active disease rather than through
genetic factors, we also examined the association with cardiovascular disease and
diabetes in 3139 ﬁrst-degree relatives (offspring: n = 930, siblings: n = 1030, and
parents: n = 1170 (Table 1)). First-degree relatives were identiﬁed through the
Swedish Multigeneration Register [17]. This register contains data on all individ-
uals born in Sweden since 1932 who were alive in 1961. Similarly we also iden-
tiﬁed ﬁrst-degree relatives to the comparison cohort, yielding 30,953 individuals.
Their characteristics are given in Table 1. Both relatives to PSC patients and rela-
tives to the comparison cohort had a mean follow-up time of close to 30 years.
Follow-up time
Start of follow-up was deﬁned as birth date, immigration or 1965, whichever
occurred later. We excluded relatives who died or emigrated before follow-up
(n = 204). Due to data irregularities that resulted in uncertain follow-up, another
9% (n = 602) of ﬁrst-degree relatives were also excluded. Follow-up ended with
death, a positive outcome (cardiovascular disease, T1D or T2D respectively), emi-
gration or end of study (Dec 31, 2004), whichever occurred ﬁrst. Data on emigra-
tion were obtained from the government agency Statistics Sweden, while data on
death date were retrieved from the Cause of Death Register maintained by the
National Board of Health and Welfare. The Cause of Death Register is regularlyJournal of Hepatology 201audited against vital status data from the National Tax ofﬁce to ensure that
100% of all deaths are recorded. In the cardiovascular analyses, the ﬁrst CVD event
was used to deﬁne overall relative risk and for each speciﬁc group of CVD diagno-
ses; and the ﬁrst event from that group of CVD diagnoses was used to deﬁnerel-
ative risk in subanalyses.
Outcome measures
Data on outcome measures were obtained from inpatient diagnoses in the Swed-
ish Patient Register [18]. This register started in 1964, and became nationwide in
1987. An extensive validation of 132 validation studies on a large range of diag-
noses found that the positive predictive value (PPV) of most diagnoses in the reg-
ister is between 85 and 95% [18], though slightly higher for ischemic heart disease
and atrial ﬁbrillation (95–100%), and slightly lower for heart failure (82–88%). No
data are available for T1D or T2D speciﬁcally but one study found that 235/236
(99%) patients with a diagnosis of diabetic ulcer actually had both diabetes and
ulcers [19]. When Zachrisson and co-workers examined some 6000 individuals
aged 0–18 years with a diagnosis of diabetes, >99% of these had T1D (as opposed
to T2D or other forms of diabetes) [20].
Outcome measures were deﬁned according to relevant international classi-
ﬁcation of disease (ICD) codes (cardiovascular diseases: ICD-10 = I00-I99 and
diabetes: ICD-10: E10 for T1D and E11 for T2D (and corresponding ICD-7-9
codes, Supplementary Table 1)). We also examined six subgroups of cardiovas-
cular disease (I) hypertensive diseases, (II) ischemic heart diseases, (III)
pulmonary heart disease and diseases of pulmonary circulation, (IV) cerebro-
vascular diseases, diseases of arteries, (V) arterioles and capillaries, (VI)
diseases of veins, lymphatic vessels and lymph nodes. Relevant ICD-codes
and deﬁnitions are listed in Supplementary Table 1. As there were no separate
codes for T1D and T2D before 1997 and the introduction of ICD-10, we deﬁned
T1D by retrieving patients whose age of ﬁrst hospital admission for diabetes
was <20 years. In total, 12 exposed and 104 unexposed individuals had records
of both T1D and T2D, using ICD-10. These 116 individuals were excluded from
the analyses.
Statistics
Themain analyses compared the PSC andnon-PSC cohorts.WeusedPoisson regres-
sion to calculate relative risks (RRs) with 95% conﬁdence intervals (CIs). We
adjusted all analyses for follow-up duration, year at entry, with further adjustment
for age at entry, county and sex to consider the matching factors. In separate anal-
yses we stratiﬁed for calendar year of entry (before or after 1987), follow-up (0–5,
6–10,P11 years) and age at end of follow-up (<40, 40–49, 50–59,P60 years).
The offspring, siblings, and parents were the units of analysis and these
groups were investigated separately to estimate the risk of cardiovascular dis-
ease, T1D and T2D among ﬁrst-degree relatives of the PSC cohort compared with
relatives of the comparison cohorts.4 vol. 60 j 802–808 803
